Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Fetal Growth Restriction
NCT02590536Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Oct 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ASP-001 in fetal growth restriction (FGR) (2 arms), sponsored by Ain Shams University. Primary endpoints: Change in Resistance Index (RI) and Pulsatility Index (PI) of the Umbilical Arteries and Change in Resistance Index (RI) and Pulsatility Index (PI) of Fetal Middle Cerebral Artery. Started Oct 2015; status: completed.
02
Drugs
ASP-001
03
Conditions
fetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT02590536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02590536.